IL90423A - Interleukin-1 inhibitors methods for producing them pharmaceutical compositions containing them isolated DNA sequences encoding interleukin-1 inhibitors and host cells and vectors containing them - Google Patents

Interleukin-1 inhibitors methods for producing them pharmaceutical compositions containing them isolated DNA sequences encoding interleukin-1 inhibitors and host cells and vectors containing them

Info

Publication number
IL90423A
IL90423A IL9042389A IL9042389A IL90423A IL 90423 A IL90423 A IL 90423A IL 9042389 A IL9042389 A IL 9042389A IL 9042389 A IL9042389 A IL 9042389A IL 90423 A IL90423 A IL 90423A
Authority
IL
Israel
Prior art keywords
interleukin
inhibitors
producing
isolated dna
pharmaceutical compositions
Prior art date
Application number
IL9042389A
Other languages
English (en)
Other versions
IL90423A0 (en
Original Assignee
Amgen Inc
Univ Colorado Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Univ Colorado Foundation filed Critical Amgen Inc
Publication of IL90423A0 publication Critical patent/IL90423A0/xx
Publication of IL90423A publication Critical patent/IL90423A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL9042389A 1988-05-27 1989-05-26 Interleukin-1 inhibitors methods for producing them pharmaceutical compositions containing them isolated DNA sequences encoding interleukin-1 inhibitors and host cells and vectors containing them IL90423A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19991588A 1988-05-27 1988-05-27
US23871388A 1988-08-31 1988-08-31
US24852188A 1988-09-23 1988-09-23
US26653188A 1988-11-03 1988-11-03

Publications (2)

Publication Number Publication Date
IL90423A0 IL90423A0 (en) 1990-01-18
IL90423A true IL90423A (en) 2000-07-26

Family

ID=27498356

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9042389A IL90423A (en) 1988-05-27 1989-05-26 Interleukin-1 inhibitors methods for producing them pharmaceutical compositions containing them isolated DNA sequences encoding interleukin-1 inhibitors and host cells and vectors containing them

Country Status (14)

Country Link
EP (3) EP0343684B1 (de)
KR (1) KR0148009B1 (de)
AT (2) ATE215966T1 (de)
CA (1) CA1341322C (de)
DE (4) DE68929387T2 (de)
ES (2) ES2018750T3 (de)
GR (1) GR900300115T1 (de)
HK (1) HK1039901A1 (de)
IE (1) IE66712B1 (de)
IL (1) IL90423A (de)
LU (1) LU90943I2 (de)
NL (1) NL300091I2 (de)
NZ (1) NZ229326A (de)
SG (1) SG59969A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
AU651955B2 (en) * 1989-11-29 1994-08-11 Amgen, Inc. Production of recombinant human interleukin-1 inhibitor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
EP0534978B1 (de) * 1990-05-01 1999-03-24 Chiron Corporation Interleukin-i antagonist und seine verwendung
JPH07509223A (ja) * 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
US5837495A (en) * 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
US5981713A (en) * 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
IT1270662B (it) * 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
AU6137396A (en) * 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Immunosuppressant
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US7205381B2 (en) 1997-04-21 2007-04-17 Schering Corporation Mammalian cytokines; related reagents and methods
CA2287254A1 (en) * 1997-04-21 1998-10-29 Schering Corporation Mammalian cytokines; related reagents and methods
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
EP1068321A2 (de) 1998-04-03 2001-01-17 Hyseq, Inc. Ein interleukin-1 rezeptor antagonist und seine verwendungen
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6680380B1 (en) 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
AU6296899A (en) * 1998-10-08 2000-04-26 Zymogenetics Inc. Interleukin-1 homolog
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL150103A0 (en) * 1999-12-10 2002-12-01 Amgen Inc Interleukin-1 receptor antagonist-like molecules and uses thereof
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US10105441B2 (en) 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
CN107337735B (zh) 2010-07-29 2021-06-22 巴扎德制药公司 嵌合il-1受体i型激动剂和拮抗剂
WO2012076193A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit exosomen und corticosteroid
WO2012076194A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit cytokin-antagonist und corticosteroid
PL2968468T3 (pl) 2013-03-13 2021-12-20 Buzzard Pharmaceuticals AB Preparaty chimerycznej cytokiny do dostarczania do oka
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341273B1 (de) * 1987-08-26 1997-01-08 Biogen, Inc. Biologische materialien, deren herstellung und verwendung in der therapie

Also Published As

Publication number Publication date
DE68906077D1 (de) 1993-05-27
DE68929387D1 (de) 2002-05-16
NL300091I1 (nl) 2002-07-01
LU90943I2 (fr) 2002-09-30
IE950317L (en) 1989-11-27
EP0343684A1 (de) 1989-11-29
HK1039901A1 (en) 2002-05-17
KR0148009B1 (ko) 1998-08-01
EP1133995A2 (de) 2001-09-19
EP0343684B1 (de) 1993-04-21
DE10299011I1 (de) 2002-07-18
EP0541920B1 (de) 2002-04-10
ATE88502T1 (de) 1993-05-15
HK1017821A1 (en) 1999-11-26
EP1133995A3 (de) 2001-09-26
ES2018750T3 (es) 1994-10-16
NL300091I2 (nl) 2002-08-01
IL90423A0 (en) 1990-01-18
SG59969A1 (en) 1999-02-22
IE891781L (en) 1989-11-27
DE343684T1 (de) 1990-11-08
KR900700618A (ko) 1990-08-16
GR900300115T1 (en) 1991-09-27
ATE215966T1 (de) 2002-04-15
EP0541920A1 (de) 1993-05-19
DE68906077T2 (de) 1993-07-29
NZ229326A (en) 1992-12-23
DE10299011I2 (de) 2006-03-16
ES2018750A4 (es) 1991-05-16
DE68929387T2 (de) 2002-08-14
CA1341322C (en) 2001-11-27
ES2176181T3 (es) 2002-12-01
IE66712B1 (en) 1996-01-24

Similar Documents

Publication Publication Date Title
IL90423A (en) Interleukin-1 inhibitors methods for producing them pharmaceutical compositions containing them isolated DNA sequences encoding interleukin-1 inhibitors and host cells and vectors containing them
NO306728B1 (no) Fremgangsmåte for fremstilling av en human rekombinant TNF inhibitor og nukleinsyre
DE68927277D1 (de) CD40 kodierende DNA
GB8818020D0 (en) Method for amplification of nucleotide sequences
GR3024031T3 (en) Production of recombinant human interleukin-1 inhibitor
FI940203L (fi) Geeni, joka koodaa eikosapeutaanihappoa syntetisoivia entsyymejä, ja menetelmä eikospentaanihapon valmistamiseksi
HUT43106A (en) Dns sequences koding proteins of flesh-i type inhibitor activity and process for producing these proteins
AU3029789A (en) Modified DNA sequences coding for mutant endotoxins of bacillus thuringiensis
RU96121465A (ru) Биосинтез рибофлавина в грибах
SE8804607D0 (sv) Aqueos formalations containing a piperidinylcyclopentylheptenoic acid derivative
AR018532A1 (es) Proteinas sustancialmente puras que contienen analogos de la beta-lipoproteina (blt); aislados de acidos nucleicos que codifican dichas proteinas yformulaciones farmaceuticas que comprenden las proteinas
EP0285361A3 (de) Reinigung von Apase-1 und Wiedererlangung des Nematodenresistenzgens
AU2687488A (en) Novel polynucleotide analogs, methods for inhibiting nucleic acid polymerases and methods for inducing synthesis of interferon
IT8522310A0 (it) Procedimento per la rimozione del gruppo formile da un estere di n-formil peptide o di n-formilamminoacido.
AU4405689A (en) New limphokines, dna sequences coding for said limphokines and pharmaceutical compositions containing said limphokines
AU1235792A (en) Syntheses, pharmaceutical composition and method of application of (2'-5') oligoadenylate analogues

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed